Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 315 Pancreatic Neoplasms 186 Carcinoma, Hepatocellular 116 Stomach Neoplasms 110 Colonic Neoplasms 84 Esophageal Neoplasms 80 Carcinoma, Non-Small-Cell Lung 80 Breast Neoplasms 78 Rectal Neoplasms 75 Ovarian Neoplasms 62 Neoplasm Metastasis 59 Lung Neoplasms 58 Neoplasms 54 Cholangiocarcinoma 53 Melanoma 45 Liver Neoplasms 45 Gastrointestinal Neoplasms 43 Prostatic Neoplasms 42 Biliary Tract Neoplasms 37 Endometrial Neoplasms 33 Squamous Cell Carcinoma of Head and Neck 31 Sarcoma 29 Carcinoma, Renal Cell 29 Esophageal Squamous Cell Carcinoma 27 Uterine Cervical Neoplasms 26 Adenocarcinoma Of Esophagus 24 Head and Neck Neoplasms 23 Urinary Bladder Neoplasms 22 Small Cell Lung Carcinoma 20 Gastrointestinal Stromal Tumors 17

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gastrointestinal × 30 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡